[의학신문·일간보사=김상일 기자]SK Bioscience (CEO Ahn Jae-yong) announced on the 6th that it has signed a joint sales contract for major vaccines with GSK. The scale of these vaccines is about 12 billion won.
 |
Target products are Tdap (tetanus, diphtheria, pertussis) vaccine’Boostrix’, meningococcal vaccine’Menbio’, hepatitis A vaccine’Habrix 1440′, measles, mumps, rubella vaccine’Priolix’, and cervical cancer vaccine ‘ There are 5 types including’Servarix’.
SK Bioscience will be in charge of selling the adult market of’Boosttrix’,’Menvio’,’Habrix 1440′, and’Prioryx’, and sales of the entire market including infants and toddlers of’Servarix’.
GSK plans to further expand its market share in the adult vaccine market through joint sales with SK Bioscience while concentrating its own sales force on the infant market of the vaccine.
An-joon Choi, head of the marketing division of SK Bioscience, said, “Through this agreement, we have secured a new growth engine that can win-win with each other in the vaccine market. It will strengthen the corporate position.”
Reporter Kim Sang-il [email protected]
<저작권자 © 의학신문, 무단 전재 및 재배포 금지>